Sublimity Therapeutics to Present at UBS Global Healthcare Conference

New York, NY., May 21, 2019 – Sublimity Therapeutics, a specialty pharmaceutical company focused on
creating meaningful new treatments for GI and immunological diseases, announced that Albert Agro,
Ph.D., Chief Executive Officer, will present at the UBS Global Healthcare Conference at 9:30 a.m. EST on
Tuesday May 21, 2019 at the Grand Hyatt New York, 109 East 42nd Street, New York.

In January, the company launched a global Phase 2b clinical trial, CYC-202. This multicenter, randomized,
double-blind, placebo-controlled, parallel-group study is intended to evaluate the safety, efficacy and
tolerability of the company’s lead drug candidate, ST-0529, in patients with moderate to severe
ulcerative colitis. Sublimity has initiated screening and enrollment of approximately 280 patients in 18
countries across Europe, Israel, Canada and the U.S.

At over 300 conferences a year across Europe, Asia Pacific and the Americas, UBS Group AG connects
corporate leaders and the global investor community, influential policy makers and industry experts.
Our award-winning┬╣ analysts and economists debate the big ideas, trends and challenges shaping the
environment, bringing attendees local knowledge with global perspective. UBS Conferences provide
professional investors a wide variety of opportunities to engage, from large scale global sector and
country specific programs, to thematic investor days and direct access to companies through post
conference ‘on the ground’ Research tours.

About Sublimity Therapeutics

Sublimity Therapeutics, a specialty pharma company with offices in Dublin, Ireland, and Solana Beach,
California, is a clinical-stage biotechnology company dedicated to identifying and creating meaningful
new therapies for unmet clinical needs in gastrointestinal and immunological diseases. Sublimity’s
priority focus is on its lead product, ST-0529, for treatment of moderate to severe ulcerative
colitis. Sublimity has a strategic collaboration with Dr. Falk Pharma GmBH that includes development
funding, milestone payments and tiered double-digit royalties for the future development and
commercialization of ST-0529 and related products in Europe. In May 2018, Sublimity announced a
financing of up to US$64 million, subject to the achievement of certain milestones, to further the
development of ST-0529. The financing was co-led by OrbiMed and Longitude Capital with participation
from HBM Healthcare Investments. For more information, please visit our website

About Ulcerative Colitis

It is estimated that ulcerative colitis affects approximately 1.7 million patients in North America, Europe
and other developed countries. The moderate to severe patient segment represents the fastest growing
market segment, with double-digit annual growth. The mainstays of treatment for this disease are anti-
TNFs; however, these drugs are limited by their toxicities and safety liabilities. A large portion of
patients are either unresponsive to initial front-line anti-TNF therapy or become refractory to treatment
within the first year. Despite the introduction of new medicines, these patients still have significant
unmet medical needs.

About Dr. Falk Pharma GmbH

Dr. Falk Pharma GmbH is one of the leading companies worldwide in gastroenterology with its products
being sold in more than 60 countries. Its pharmaceuticals are used successfully to treat inflammatory
bowel disease, cholestatic liver disease, irritable bowel syndrome, constipation, and for colon cleansing
prior to colonoscopies. The Falk Foundation, which is associated with the company, provides medical
information via international symposia, forums, postgraduate courses and literature services. Over the
past 45 years the Falk Foundation has sponsored more than 200 international Falk symposia and
workshops in which over 100,000 researchers and physicians from 110 countries have come together to
advance knowledge in gastroenterology and hepatology.

Forward-Looking Statements

This press release contains forward-looking statements. Such forward-looking statements involve
substantial risks and uncertainties. We have tried, wherever possible, to identify such statements by
using words such as “will,” “may,” “could,” “likely,” “ongoing,” “anticipate,” “estimate,” “expect,”
“project,” “intend,” “plan,” “believe,” “target,” “forecast,” “goal,” “objective,” “aim” and other words
and terms of similar meaning or by using future dates in connection with any discussion thereof. In
particular, statements, express or implied, concerning future actions, conditions or events, future
operating results, including, but not limited to, the potential medical benefits of ST-0529, the perceived
potential opportunity in the ulcerative colitis market for an oral alternative, the intended launch of the
Phase 2b clinical trial and the success of such clinical trial and the launch and success of any future
clinical trials, the ability to obtain required regulatory approval for ST-0529, and risks related Sublimity
meeting some or all of the milestones required to be met for future funding by investors, are forward-
looking statements. We cannot guarantee that any forward-looking statement will be realized, although
we believe we have been prudent in our plans and assumptions. Achievement of anticipated results is
subject to substantial risks, uncertainties and inaccurate assumptions. Should known or unknown risks
or uncertainties materialize, or should underlying assumptions prove inaccurate, actual results could
vary materially from past results and those anticipated, estimated or projected. You should bear this in
mind as you consider forward-looking statements, and you are cautioned not to put undue reliance on
forward-looking statements. Sublimity undertakes no obligation to publicly update forward-looking
statements, whether as a result of new information, future events or otherwise, except as required by


Company Contact:
Albert Agro
President & CEO
Sublimity Therapeutics

David Schull
Russo Partners LLC
(212) 845-4271